Skip to main content
Journal cover image

Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice.

Publication ,  Journal Article
Friedman, HS; Keir, ST; Houghton, PJ; Lawless, AA; Bigner, DD; Waters, SJ
Published in: Cancer Chemother Pharmacol
November 2001

PURPOSE: This study was conducted to define the activity of irofulven in the treatment of a series of xenografts derived from human glioblastoma multiforme growing subcutaneously and intracranially in athymic nude mice. METHODS: Athymic mice bearing subcutaneous or intracranial tumors were treated with irofulven at a 10% lethal dose with responses compared to tumor-bearing mice treated with drug vehicle. RESULTS: Irofulven was active against all tumor lines tested with growth delays ranging from 5.6 to 81.6 days (all values statistically significant, P < or = 0.001). Irofulven also produced a statistically significant (P < or = 0.001) increase in the median survival of mice bearing D-456 intracranial xenografts with a 162% increase in median survival. CONCLUSIONS: Irofulven is active in a spectrum of human glioblastoma multiforme-derived xenografts and evaluation in patients with this neoplasm is warranted.

Duke Scholars

Published In

Cancer Chemother Pharmacol

DOI

ISSN

0344-5704

Publication Date

November 2001

Volume

48

Issue

5

Start / End Page

413 / 416

Location

Germany

Related Subject Headings

  • Transplantation, Heterologous
  • Sesquiterpenes
  • Oncology & Carcinogenesis
  • Mice, Nude
  • Mice, Inbred BALB C
  • Mice
  • Male
  • Humans
  • Glioblastoma
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Friedman, H. S., Keir, S. T., Houghton, P. J., Lawless, A. A., Bigner, D. D., & Waters, S. J. (2001). Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice. Cancer Chemother Pharmacol, 48(5), 413–416. https://doi.org/10.1007/s002800100358
Friedman, H. S., S. T. Keir, P. J. Houghton, A. A. Lawless, D. D. Bigner, and S. J. Waters. “Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice.Cancer Chemother Pharmacol 48, no. 5 (November 2001): 413–16. https://doi.org/10.1007/s002800100358.
Friedman HS, Keir ST, Houghton PJ, Lawless AA, Bigner DD, Waters SJ. Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice. Cancer Chemother Pharmacol. 2001 Nov;48(5):413–6.
Friedman, H. S., et al. “Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice.Cancer Chemother Pharmacol, vol. 48, no. 5, Nov. 2001, pp. 413–16. Pubmed, doi:10.1007/s002800100358.
Friedman HS, Keir ST, Houghton PJ, Lawless AA, Bigner DD, Waters SJ. Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice. Cancer Chemother Pharmacol. 2001 Nov;48(5):413–416.
Journal cover image

Published In

Cancer Chemother Pharmacol

DOI

ISSN

0344-5704

Publication Date

November 2001

Volume

48

Issue

5

Start / End Page

413 / 416

Location

Germany

Related Subject Headings

  • Transplantation, Heterologous
  • Sesquiterpenes
  • Oncology & Carcinogenesis
  • Mice, Nude
  • Mice, Inbred BALB C
  • Mice
  • Male
  • Humans
  • Glioblastoma
  • Female